The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
(Source: Endocrine-Related Cancer)
Source: Endocrine-Related Cancer - May 31, 2017 Category: Endocrinology Authors: Law, A. M. K., Lim, E., Ormandy, C. J., Gallego-Ortega, D. Tags: Erratum Source Type: research
Association between changes in fat distribution and biomarkers for breast cancer
We assessed the associations between changes in total and abdominal fat and changes in biomarkers for breast cancer risk using data of the SHAPE-2 trial. In the SHAPE-2 trial, 243 postmenopausal overweight women were included. The intervention in this trial consisted of 5-6 kg weight loss either by diet only or exercise plus diet. After 16 weeks, we measured serum sex hormones, inflammatory markers, total body fat (measured by DEXA scan) and intra and subcutaneous abdominal fat (measured by MRI). Associations between changes in different body fat depots and biomarkers were analysed by linear regression using the study coho...
Source: Endocrine-Related Cancer - May 23, 2017 Category: Endocrinology Authors: van Gemert, W. A., Monninkhof, E. M., May, A. M., Elias, S. G., van der Palen, J., Veldhuis, W., Stapper, M., Stellato, R. K., Schuit, J. A., Peeters, P. H. Tags: Research Source Type: research
Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours, which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and in gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary, and parathyroid glands. Due to the rarity of these tumours and the lack of prospective studies, current guidelines are mostly based on r...
Source: Endocrine-Related Cancer - May 23, 2017 Category: Endocrinology Authors: Angelousi, A., Dimitriadis, G. K., Zografos, G., Nolting, S., Kaltsas, G., Grossman, A. Tags: Review Source Type: research
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking advantage of the most modern techniques, in the perspective of personalized medicine and appropriate resource utilization. This review summarizes the available data on the possible role of circulating tumor cells and microRNAs as prognostic m...
Source: Endocrine-Related Cancer - May 23, 2017 Category: Endocrinology Authors: Zatelli, M. C., Grossrubatscher, E. M., Guadagno, E., Sciammarella, C., Faggiano, A., Colao, A. Tags: Review Source Type: research
Molecular imaging in the investigation of hypoglycaemic syndromes and their management
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors (somatostatin receptors (SSTRs) and glucagon-like peptide-1 receptor (GLP-1R)) the amine precursor uptake and decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-l-fluoro-l-3,4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]fluoro-2-deoxy-d-glucose (FDG). Accurate preoperative localisation and staging is critical to enable direct...
Source: Endocrine-Related Cancer - May 23, 2017 Category: Endocrinology Authors: Pattison, D. A., Hicks, R. J. Tags: Review Source Type: research
Very low expression of PD-L1 in medullary thyroid carcinoma
(Source: Endocrine-Related Cancer)
Source: Endocrine-Related Cancer - May 23, 2017 Category: Endocrinology Authors: Bongiovanni, M., Rebecchini, C., Saglietti, C., Bulliard, J.-L., Marino, L., de Leval, L., Sykiotis, G. P. Tags: Research Letter Source Type: research
The purine receptor P2X7R regulates the release of pro-inflammatory cytokines in human craniopharyngioma
In conclusion, the results suggest that P2X7R may promote IL-6, IL-8 and MCP-1 production and secretion and contribute to the invasion and adhesion of CPs to the surrounding tissue. (Source: Endocrine-Related Cancer)
Source: Endocrine-Related Cancer - May 15, 2017 Category: Endocrinology Authors: Nie, J., Huang, G.-l., Deng, S.-Z., Bao, Y., Liu, Y.-W., Feng, Z.-P., Wang, C.-H., Chen, M., Qi, S.-T., Pan, J. Tags: Research Source Type: research
Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model
Anaplastic thyroid cancer is one of the most lethal diseases, and a curative therapy does not exist. Doxorubicin, the only drug approved for anaplastic thyroid cancer treatment, has a very low response rate and causes numerous side effects among which cardiotoxicity is the most prominent. Thus, doxorubicin delivery to the tumor site could be an import goal aimed to improve the drug efficacy and to reduce its systemic side effects. We recently reported that, in human anaplastic thyroid cancer cell lines, combining doxorubicin-loaded nanobubbles with extracorporeal shock waves, acoustic waves used in lithotripsy and orthoped...
Source: Endocrine-Related Cancer - May 15, 2017 Category: Endocrinology Authors: Marano, F., Frairia, R., Rinella, L., Argenziano, M., Bussolati, B., Grange, C., Mastrocola, R., Castellano, I., Berta, L., Cavalli, R., Catalano, M. G. Tags: Research Source Type: research
Risk factors for venous thromboembolism in patients treated for differentiated thyroid carcinoma
In conclusion, surgery and presence of distant metastases are independent risk factors for developing VTE in DTC patients. The risk factors identified in this study could be considered when making decisions regarding thromboprophylaxis for patients with thyroid cancer. (Source: Endocrine-Related Cancer)
Source: Endocrine-Related Cancer - May 5, 2017 Category: Endocrinology Authors: van der Boom, T., Klein Hesselink, E. N., Kooistra, H. A. M., Meijer, K., van der Horst-Schrivers, A. N. A., Lefrandt, J. D., Links, T. P. Tags: Research Source Type: research
Apc inactivation, but not obesity, synergizes with Pten deficiency to drive intestinal stem cell-derived tumorigenesis
Obesity is a major risk factor for colorectal cancer and can accelerate Lgr5+ intestinal stem cell (ISC)-derived tumorigenesis after the inactivation of Apc. However, whether non-canonical pathways involving PI3K-Akt signaling in ISCs can lead to tumor formation, and if this can be further exacerbated by obesity is unknown. Despite the synergy between Pten and Apc inactivation in epithelial cells on intestinal tumor formation, their combined role in Lgr5+-ISCs, which are the most rapidly dividing ISC population in the intestine, is unknown. Lgr5+-GFP mice were provided low-fat diet (LFD) or high-fat diet (HFD) for 8 months...
Source: Endocrine-Related Cancer - May 5, 2017 Category: Endocrinology Authors: Tabrizian, T., Wang, D., Guan, F., Hu, Z., Beck, A. P., Delahaye, F., Huffman, D. M. Tags: Research Source Type: research
Targeting the TSH receptor in thyroid cancer
Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermor...
Source: Endocrine-Related Cancer - May 5, 2017 Category: Endocrinology Authors: Rowe, C. W., Paul, J. W., Gedye, C., Tolosa, J. M., Bendinelli, C., McGrath, S., Smith, R. Tags: Review Source Type: research
Paraneoplastic endocrine syndromes
The majority of neoplasms are responsible for symptoms caused by mass effects to surrounding tissues and/or through the development of metastases. However, occasionally neoplasms, with or without endocrine differentiation, acquire the ability to secrete a variety of bioactive substances or induce immune cross-reactivity with the normal tissues that can lead to the development of characteristic clinical syndromes. These syndromes are named endocrine paraneoplastic syndromes when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Endocrine paraneopl...
Source: Endocrine-Related Cancer - May 5, 2017 Category: Endocrinology Authors: Dimitriadis, G. K., Angelousi, A., Weickert, M. O., Randeva, H. S., Kaltsas, G., Grossman, A. Tags: Review Source Type: research
Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up. Anatomical imaging was performed before therapy and in fol...
Source: Endocrine-Related Cancer - April 18, 2017 Category: Endocrinology Authors: Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., de Herder, W. W., Feelders, R. A., Krenning, E. P., Kwekkeboom, D. J. Tags: Research Source Type: research
Timing of multikinase inhibitor initiation in differentiated thyroid cancer
There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients ...
Source: Endocrine-Related Cancer - April 18, 2017 Category: Endocrinology Authors: Brose, M. S., Smit, J., Lin, C.-C., Pitoia, F., Fellous, M., DeSanctis, Y., Schlumberger, M., Tori, M., Sugitani, I. Tags: Research Source Type: research
MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine
The high degree of conservation in microRNA from Caenorhabditis elegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microRNA to address these changes holds significant promise. However, prostate, ovarian and breast cancers are heterogeneous and face issues of evolving therapeutic resistance. The transforming growth factor-beta (TGFβ) signaling axis plays an important role in the progression of these cancers by regulating mi...
Source: Endocrine-Related Cancer - April 18, 2017 Category: Endocrinology Authors: Smith, B., Agarwal, P., Bhowmick, N. A. Tags: Review Source Type: research
